ADVM News and Press, Adverum Biotechnologies Inc.

2025-12-09 09:29:13 ET More on Eli Lilly, Adverum Biotechnologies Mounjaro In China: Assessing Market Potential And Risks Eli Lilly and Company (LLY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript Eli Lilly: The GLP-1 Leader's Sky-High P/E Makes...

Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition PR Newswire INDIANAPOLIS , Dec. 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)  and Adverum Biotechnologies, Inc. (NASDAQ: ADVM) today announced that the tender offer ...

REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy as a potential One And Done TM treatment to preserve sight for life, today announced that it has mailed a letter to it...

Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights PR Newswire Shareholders should contact the firm immediately as there may be limited time to enforce your rights.   NEW YORK , Nov. 19, 2025 /PRNewswire/ -- H...

VEON Ltd. (VEON) is expected to report $1.21 for Q3 2025 eToro Group Ltd. (ETOR) is expected to report $0.52 for Q3 2025 KE Holdings Inc American Depositary Shares (each representing three Class A) (BEKE) is expected to report $0.09 for Q3 2025 CoreWeave Inc. (CRWV) is expected to rep...

Hess Midstream LP Class A Representing Limited Partner Interests (HESM) is expected to report $0.73 for Q3 2025 IDEAYA Biosciences Inc. (IDYA) is expected to report $0 for Q3 2025 Unum Group (UNM) is expected to report $2.15 for Q3 2025 CNA Financial Corporation (CNA) is expected to r...

HALPER SADEH LLC ENCOURAGES ADVM, PLYM, RNA SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS PR Newswire Shareholders should contact the firm immediately as there may be limited time to enforce your rights.   NEW YORK , Oct. 27, 2025 /PRNewswire/ -- Halper S...

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) to Eli Lilly and Company is fair to Adverum sharehol...

2025-10-25 15:15:10 ET More on M&A tickers, etc. DocGo: Revenue Collapse Overshadows Acquisition, Is Cheap But Still A Hold Blackstone Q3: Distributable Earnings Up +48% (Rating Upgrade) Old Republic International Corporation (ORI) Q3 2025 Earnings Call Transcrip...

2025-10-24 19:22:50 ET Joon Lee from Truist Financial issued a price target of $5.00 for ADVM on 2025-10-24 17:52:24. The adjusted price target was set to $5.00. At the time of the announcement, ADVM was trading at $4.07. The overall price target consensus is at $5.00 wi...